Leerink Trims PT on Illumina (ILMN) to $185 Following Negative Q3 Preannouncement

Go back to Leerink Trims PT on Illumina (ILMN) to $185 Following Negative Q3 Preannouncement

Illumina (ILMN) PT Slashed to $137 at Goldman Sachs

October 6, 2015 9:28 AM EDT

Goldman Sachs analyst Isaac Ro reiterated a Neutral rating and slashed his price target on Illumina (NASDAQ: ILMN) to $137.00 (from $230.00) after a negative Q3 preannouncement.

Ro commented, "We maintain our Neutral rating but lower our price target to reflect our lower estimates and target multiple. In essence, we attribute the 3Q miss to a product... More

Canaccord Genuity Reiterates Buy on Illumina (ILMN) Following 3Q15 Preliminary Results

October 6, 2015 8:37 AM EDT

Canaccord Genuity reiterated a Buy rating and $250.00 price target on Illumina (NASDAQ: ILMN) following the company's preliminary 3Q15 earnings results. ILMN reported preliminary 3Q15 revenues of ~$550M compared to the Streets $569M, citing weakness in Asia and Europe and desktop sequencers.

Analyst... More

Piper Jaffray Cuts Price target on Illumina (ILMN) Following Preliminary 3Q15 Results

October 6, 2015 8:01 AM EDT

Piper Jaffray maintained an Overweight rating on Illumina (NASDAQ: ILMN), and cut the price target to $220.00 (from $230.00), following the announced preliminary 3Q15 results. Illumina issued results with revenue increasing ~14% yoy to $550M, below in-line $569.2M estimates and 3Q15 EPS below the Street's $0.83. Management attributed the miss to a... More

Illumina (ILMN) PT Lowered to $200 at UBS; Says May Be Time to Buy

October 6, 2015 7:44 AM EDT

UBS analyst Jonathan Groberg lowered his price target on Illumina (NASDAQ: ILMN) to $200.00 (from $250.00) after the company's negative pre-announcement but maintained a Buy rating.

Groberg noted sequencing consumables and instrument sales for the HiSeq family were strong, although desktop sales (e.g. MiSeq & NextSeq) were softer than expected. Geographically, instrument sales were particularly weak in Europe and Japan. Management blamed much of the miss on poor execution in... More

Mizuho Securities Downgrades Illumina (ILMN) to Neutral

October 6, 2015 6:26 AM EDT

Mizuho Securities downgraded Illumina (NASDAQ: ILMN) from Buy to Neutral with a price target of $150.00 (from $250.00) following the company's negative 3Q and 4Q pre-announcement, which was driven by desktop weakness.

Analyst Eric Criscuolo commented, "While we saw near-term risks around strong comps,... More

Illumina (ILMN) Prelim. Q3 Revenue Misses Expectations; Guides Q4 Revenue Below Consensus

October 5, 2015 4:07 PM EDT

Illumina (NASDAQ: ILMN) announced estimated third quarter revenue of approximately $550 million, a 14% increase compared to $481 million in the third quarter of 2014 and 18% growth on a constant currency basis. This estimate, which is unaudited, is based on management's preliminary financial analysis.

*** The Street sees Q3 revenue of $570 million.

Demand for sequencing consumables and the HiSeq family of instruments remained strong during the quarter, while instrument sales in the desktop family... More